BiotechTube
HEPHAISTOS-Pharma

HEPHAISTOS-Pharma

Paris, France· Est.
hephaistos-pharma.fr
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

HEPHAISTOS-Pharma is a private, preclinical-stage biotech tackling the major challenge of non-responsive 'cold' tumors in oncology. The company has developed a proprietary platform of systemic, detoxified TLR4 agonist immunotherapies designed to broadly activate the innate immune system against cancer. With €18.1M in seed and non-dilutive funding, a strong scientific founding team, and an orphan drug designation for its lead candidate in osteosarcoma, HEPHAISTOS is advancing towards first-in-human trials expected in 2027.

Oncology

Technology Platform

Platform for engineering detoxified and augmented Toll-like Receptor 4 (TLR4) agonist immunotherapies designed for systemic administration to convert 'cold' tumors into immunologically 'hot' tumors.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The primary opportunity lies in addressing the vast population of cancer patients with 'cold,' immunotherapy-resistant tumors, a multi-billion dollar unmet need.
Orphan drug designation in osteosarcoma provides a accelerated regulatory pathway and market exclusivity potential.
Success could also position HEPHA-440 as a combination backbone to rejuvenate the larger market for checkpoint inhibitors.

Risk Factors

Key risks include the translational risk from preclinical models to human safety and efficacy, particularly concerning systemic toxicity of an immune activator.
The company faces significant funding needs to reach and through clinical trials, and operates in a competitive landscape of innate immune agonists.

Competitive Landscape

HEPHAISTOS competes in the innate immune agonist space, which includes companies developing STING, TLR, and RIG-I agonists for oncology. Differentiation hinges on its systemic, detoxified TLR4 approach. Competitors range from large pharma (e.g., BMS with STING programs) to biotechs, many focusing on intratumoral delivery to manage toxicity.

More companies in Immunotherapy / Immuno-Oncology →More companies in France →